Skip to content
NewsBlazeAU – Lifestyle
Author:
Rezolute, Inc.
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
June 2, 2026
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
May 12, 2026
Rezolute to Participate in Upcoming Investor Conferences
May 11, 2026
←
Previous Page
1
2